Results 161 to 170 of about 10,242 (284)

Muscle-Specific Dosing of OnabotulinumtoxinA in Post-Stroke Upper-Limb Spasticity: A Descriptive Literature Review. [PDF]

Toxins (Basel)
Cisowska-Adamiak M, Mackiewicz-Milewska M, Miller ED.   +2 more
europepmc   +1 more source

Encephalopathy: Cause, Pathogenesis, and Treatment

MedComm, Volume 7, Issue 6, June 2026.
Various encephalopathies (sepsis‐associated, hepatic, hypoxic–ischemic, diabetic, uremic, toxic) have incompletely elucidated pathogenesis, which severely restricts targeted therapy development. Small molecule drugs show unique multitarget potential but face toxicity, poor blood–brain barrier penetration and unclear specificity.
Shimeng Lv, Xia Zhong, Ruirui Shang, Linghui Kong, Yufei Huang, Yuexiang Ma, Jing Teng, Sheng Wei   +7 more
wiley   +1 more source

Reply to Tarihci Cakmak et al. Comment on "Kang et al. The Effective Way of Botulinum Toxin Injection to Reduce Bite Force: Preliminary Study. <i>Toxins</i> 2025, <i>17</i>, 519". [PDF]

Toxins (Basel)
Kang KH, Jung JK, Byun JS, Kim JR.
europepmc   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025

Neurourology and Urodynamics, Volume 45, Issue 5, Page 904-913, June 2026.
ABSTRACT Introduction Management of overactive bladder (OAB) has a stepwise approach in adults and children. This does not account for individual patient variations, which may explain suboptimal outcomes in many patients. Distinct OAB profiles, based on patient characteristics, symptoms, urodynamic findings and imaging have been discussed in Part 1 ...
Michel Wyndaele, Michael Samarinas, Apostolos Apostolidis, D. Carolina Ochoa, Giovanni Mosiello, Brigitte Schurch, Pradeep Tyagi, Alan Wein, Paul Abrams, John E. Speich   +9 more
wiley   +1 more source

Botulinum Toxin as Targeted Neuromodulation in Complex Regional Pain Syndrome: An Anatomy-Informed Mechanistic Review. [PDF]

Toxins (Basel)
Suputtitada A.
europepmc   +1 more source

Should We Consider Sacral Nerve Stimulation as a Treatment for Neurogenic Lower Urinary Tract Dysfunction? ICI‐RS 2025

Neurourology and Urodynamics, Volume 45, Issue 5, Page 945-950, June 2026.
ABSTRACT Aims To explore the boundary of clinical use of sacral nerve stimulation (SNS) in neurogenic lower urinary tract dysfunction (NLUTD), identifying barriers to approval and early‐impact research questions. Methods This review is derived from a proposal discussion at the International Consultation on Incontinence‐Research Society in Bristol in ...
Marcus J. Drake, Mathijs de Rijk, Stefania Musco, Jalesh Panicker, Michał Późniak, Nikita Bhatt, Brigitte Schurch   +6 more
wiley   +1 more source

Clinical Effectiveness of IncobotulinumtoxinA Using a Standardized Protocol in the Management of Myogenous Temporomandibular Disorders: A 12-Month Retrospective Study. [PDF]

Toxins (Basel)
Ângelo DF, Cardoso HJ, Sarkis M, Santos K, Maffia F, Sanz D, Salvado F.   +6 more
europepmc   +1 more source

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

Neurourology and Urodynamics, Volume 45, Issue 5, Page 929-936, June 2026.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk, Michel Wyndaele, Ana Charrua, Christopher Fry, Paul Abrams, Gommert A. van Koeveringe, Anthony J. Kanai, Marcus J. Drake   +7 more
wiley   +1 more source

Design and Characterization of Recombinant and Chimeric BoNT/A Neurotoxins with Receptor-Binding Domain Grafting. [PDF]

Toxins (Basel)
Pan S, Ye Y, Li Y, Fu H, Wang J.
europepmc   +1 more source